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Abstract
Background—The American Heart Association/American Stroke Association (AHA/ ASA) 
recommended an expansion of the time window for acute ischemic stroke (AIS) reperfusion with 
intravenous (IV) recombinant tissue plasminogen activator (rt-PA) from 3 to 4.5 hours after 
symptom onset. We examine rates of IV and intraarterial (IA) reperfusion before and after the 
recommendations to track guideline adoption in community practice.
Methods—Patients with AIS in the Paul Coverdell National Acute Stroke Registry spanning 
years 2007-2012 were identified. Trends in rates of IV rt-PA versus IA therapy were examined. 
Outcomes included symptomatic intracerebral hemorrhage (sICH), in-hospital mortality, ability to 
ambulate at discharge, and discharge destination.
Results—From 2007 to 2012, there were 182,235 AIS patients (median age, 72 years; 51.5% 
women) in the database at the time of analysis. AIS patients receiving IV rt-PA increased 
significantly from 3.7% in 2007 to 5.1% in 2012 in the ≤3 hours time window and from .2% in 
2007 to 1.3% in 2012 in the 3-4.5 hours time window (P <.001 for both). There was also a 
significant increase in the rate of IA therapy between 2007 and 2012 (P <.001). There was a 
significant decrease in the rate of sICH among patients who received any reperfusion between 
2007 and 2012.
Conclusions—There was a trend for increased utilization of IV rt-PA in the 0-3 hours and the 
3-4.5 hours time windows, which began around the same time as the publication of AHA/ASA 
recommendations in 2009. This increase was associated with an increase in IA treatment rates 
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along with a decrease in overall sICH rates for patients receiving any reperfusion. Key Words: 
Expanded time window—ischemic stroke—thrombolysis—trend analysis.
Background
In May 2009, the American Heart Association/American Stroke Association (AHA/ASA) 
recommended an expansion of the time window for acute ischemic stroke (AIS) therapy 
with intravenous (IV) recombinant tissue plasminogen activator (rt-PA) from 3 to 4.5 hours 
after symptom onset based on the European Cooperative Acute Stroke Study III Trial and 
the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis 
Registry study.1-3 A pooled analysis found no differences between the 3-4.5 hours cohort 
and ≤3 hours cohort with respect to symptomatic intracerebral hemorrhage (sICH) rates, 
mortality, and modified Rankin Scale (mRS) score.4 National estimates of IV rt-PA 
utilization range from 1.8% to 5.2% as most AIS patients arrive outside the time window for 
IV thrombolysis.5 With expansion of the time window, a larger group of patients could 
become eligible for treatment. We examined rates of IV rt-PA use before and after the 
AHA/ASA recommendations for an expanded time window for IV thrombolysis to 
determine the impact of these guideline changes on community practice. Rates of intra-
arterial (IA) therapies for AIS during this same period were also analyzed for shifts in 
response to the expanded IV time window.
Methods
The study population included patients admitted with a diagnosis of AIS from 2007 to 2012. 
The Paul Coverdell National Acute Stroke Registry (PCNASR) is an ongoing acute stroke 
quality improvement program funded by the Centers for Disease Control and Prevention 
(CDC). The PCNASR provides feedback to states on adherence to guidelines of care to 
improve care quality for hospitalized patients with stroke and transient ischemic attack. 
During our study period hospitals across 6 states (Georgia, Massachusetts, Michigan, 
Minnesota, North Carolina, and Ohio) participated in the PCNASR. Hospital participation is 
voluntary. Trained abstractors from participating hospitals collect detailed information on 
stroke and transient ischemic attack admissions concurrent with or soon after patient care 
using standard data definitions provided by the CDC.6,7
Trends by year were examined for rates of IV and IA rt-PA. Patients receiving either of 
these therapies were divided as follows: (1) treatment ≤3 hours from symptom onset; (2) 
treatment 3-4.5 hours from symptom onset; and (3) treatment >4.5 hours from symptom 
onset. Outcome measures included rates of sICH, in-hospital mortality, ability to ambulate at 
discharge, and discharge destination. Categoric variables were compared across treatment 
groups using 2-tailed Fisher exact or chi-square tests. Continuous variables were compared 
using the Wilcoxon–Mann–Whitney rank test or the Kruskal–Wallis test. Statistical analyses 
were performed at the CDC using SAS software (version 9.2; SAS Institute, Cary, NC).
Results
From 2007 to 2012, there were 182,235 patients (Table 1; median age, 72 years; 51.5% 
women) admitted with AIS in the PCNASR database. The proportion of all AIS patients 
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receiving IVrt-PA increased significantly from 3.7% in 2007 to 5.1% in 2012 in the ≤3 
hours and from .2% in 2007 to 1.3% in 2012 in the 3-4.5 hours time windows, excluding 
patients who received IV rt-PA before transfer (P <.001 for both, Table 2, Fig 1). Patients 
who received IV rt-PA before transfer to another hospital increased from 1% in 2007 to 
2.6% in 2012 (P <.001). There was a significant change in IA therapy rates between 2007 (.
4%) and 2012 (2%), including those who received IA therapy only and those who received 
both IV and IA rt-PA (P <.001, Table 2). We have included analyses of those patients who 
were documented to have baseline National Institutes of Health Stroke Scale (NIHSS) 
scores. Among these patients, the trend for using IV rt-PA in the ≤3 hours window and the 
3-4.5 hours window increased significantly. However, it is noted that there was no 
significant change in the utilization of IA therapy among those with a documented NIHSS 
score (Table 2).
Overall, patients receiving combined IV and IA therapy had the highest rates of sICH, life-
threatening complications, and in-hospital mortality. The overall rates of sICH among those 
who received either IV only treatment or IA only treatment decreased significantly over time 
(P =.003 for both, Table 3). When stratified by NIHSS score ,10 and ≥10, patients receiving 
IV rt-PA only had the highest rates of ambulation at time of discharge and discharge to 
home compared with those who received either IA therapy or both IV and IA therapies 
(Table 4).
Discussion
Rates of IV rt-PA use between 3 and 4.5 hours after symptom onset significantly increased 
after publication of the AHA/ASA recommendations in 2009; however, this increase began 
before the publication of the updated guidelines. Of interest, there was also a significantly 
higher rate of IV rt-PA use in the ≤3 hours group, which began in 2007 also. Because of 
known time lag for diffusion of innovation, it maybe too early to see additional trends that 
might be related to the updated guidelines as opposed to those from pre-existing secular 
trends. The benefit of rt-PA is time dependent, and it is most effective when given in the 
first 90 minutes after symptom onset.1,2,8 It has been suggested that patients who are eligible 
to receive IV rt-PA within the 3 hours time window might experience delays in receiving it, 
possibly because of a reduced sense of urgency after the time window expansion.8,9 
However, our data do not support evidence of reduced usage in the ≤3 hours time window in 
favor of the extended time window. In fact, the rate of increase in IV rt-PA use from 2007 to 
2012 was identical for both time windows.
The Food and Drug Administration has yet to approve IV rt-PA use for AIS beyond 3 hours 
from symptom onset.10 We have shown that community practice is following guideline 
recommendations regarding the extended time window although its use is much less than in 
the standard time window. We demonstrated evidence of improved outcomes over time.
We hypothesized that IA treatment would decline because of the expanded IV time window. 
IA therapy is traditionally used in circumstances where patients are ineligible for IV rt-PA 
with the most common reason being delay in presentation from symptom onset. IA 
treatment rates were increased across the observation period, but there was no change in 
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favorable outcomes among those who received IA treatment over time. The more favorable 
outcomes among those who received IV thrombolysis are likely related to earlier time to 
treatments or lower initial stroke severity compared with those who received IA reperfusion. 
We note, however, that the rates of sICH among those receiving IV or IA therapies had 
reduced significantly over our study period; this maybe the result of a higher number of 
patients presenting with less severe strokes as defined by NIHSS ,10 later in the study period 
compared with the beginning.
The Interventional Management of Stroke III (IMS III), Mechanical Retrieval and 
Recanalization of Stroke Clots Using Embolectomy (MR RESCUE), and Local Versus 
Systemic Thrombolysis for Acute Ischemic Stroke Expansion (SYNTHESIS) trials reported 
in early 2013 that IA therapies are not superior to traditional interventions. It was suggested 
that the prolonged time to treatment from symptom onset maybe the reason for the inability 
to show improved rates of disability and mortality despite the ability to recanalize occluded 
vessels.11-13 This may lead to an increased trend in administering IV rt-PA within the 3-4.5 
hours window.
Study strengths are the large number of patients and the multistate data from a variety of 
hospitals gathered during regular care delivery rather than a clinical trial. A weakness 
includes outcome assessment by clinical features rather than formal scales such as the mRS 
score. However, it has been shown that discharge destination could act as a surrogate for 
mRS score and have high predictive values of determining rates of death and disability.14 
Baseline NIHSS scores were only recorded in 55.2% of patients in our cohort, which causes 
difficulties in ascertaining baseline disability in a minority of patients; however, the rate of 
reporting NIHSS scores in our cohort continued to increase substantially over time.
Conclusion
We conclude that guideline recommendations on IV reperfusion after AIS in an expanded 
time window are slowly being adopted into community practice. The rates of thrombolysis 
in the original ≤3 hours window did not decrease in response to the recommended time 
window expansion. The increased IV use has coincided with increased rates of IA 
reperfusion. Future studies can examine further trends in IV and IA treatments for AIS now 
that recent studies have shown nonsuperiority of IA therapies to traditional interventions.
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Number of patients receiving intravenous thrombolytic treatment based on time to treatment 
by year.
*Rates of treatment in the < 3 hour window did not decline in response to expansiion of 
treatment time window
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Table 1
Demographic and baseline characteristics among acute ischemic stroke patients, 2007-2012















 Median 72 73 72 71 71 71
 Range 18-105 18-107 18-106 18-111 18-119 18-106
 Mean (SE) 70.42 (.13) 70.43 (.10) 70.55 (.09) 70.03 (.08) 69.99 (.07) 69.95 (.07)
Gender
 Female 7007 (51.9) 11,608 (52.6) 14,509 (51.9) 18,121 (51.4) 20,695 (51.5) 21,986 (50.8)
Race
 Black 2931 (21.7) 4397 (19.9) 5598 (20.0) 7667 (21.7) 8579 (21.4) 9230(21.3)
 White 10,018 (74.2) 16,418 (74.3) 20,790 (74.3) 25,589 (72.5) 29,239 (72.8) 31,640(73.2)
 Other 550 (4.1) 1271 (5.8) 1575 (5.6) 2033 (5.8) 2330 (5.8) 2380 (5.5)
Admission NIHSS in groups
 NIHSS < 10 3419 (25.3) 5959 (27.0) 8810 (31.5) 14,256 (40.4) 18,348 (45.7) 23,244 (53.7)
 NIHSS 10-19 887 (6.6) 1655 (7.5) 2227 (8.0) 3539 (10.0) 4169 (10.4) 5003 (11.6)
 NIHSS > 20 457 (3.4) 749 (3.4) 1107 (4.0) 1885 (5.3) 2186 (5.4) 2677 (6.2)
 Missing 8736 (64.7) 13,723 (62.1) 15,819 (56.6) 15,609 (44.2) 15,445 (38.5) 12,326 (28.5)
Abbreviations: NIHSS, National Institutes of Health Stroke Scale; SE, standard error.
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Table 2
Type of rt-PA given among all patients and among those with NIHSS recorded
N (%) or statistics by year
Variables Year 2007 Year 2008 Year 2009 Year 2010 Year 2011 Year 2012
Total 13,499 22,086 27,963 35,289 40,148 43,250
rt-PA group
 IV therapy* 576 (4.3) 1028 (4.7) 1482 (5.3) 2162 (6.1) 2434 (6.1) 2923 (6.8)†
 IA therapy* 38 (.3) 178 (.8) 272 (1.0) 366 (1.0) 538 (1.3) 649 (1.5)†
 IV + IA therapy* 10 (.1) 47 (.2) 75 (.3) 124 (.4) 158 (.4) 226 (.5)†
 IV therapy‡ 130(1.0) 298 (1.3) 491 (1.8) 735 (2.1) 900 (2.2) 1109(2.6)†
 No rt-PA 12,745 (94.4) 20,535 (93.0) 25,643 (91.7) 31,902 (90.4) 36,118 (90.0) 38,343 (88.7)
 Any rt-PA 754 (5.6) 1551 (7.0) 2320 (8.3) 3387 (9.6) 4030 (10.0) 4907 (11.3)†
IV rt-PA only: Symptom onset to treatment time
 ≤3 hours 506 (3.7) 851 (3.9) 1163(4.2) 1657 (4.7) 1821 (4.5) 2215 (5.1)†
 3-4.5 hours 33 (.2) 85 (.4) 201 (.7) 373 (1.1) 463 (1.2) 547 (1.3)†
 Beyond 4.5 hours 3 (.0) 7 (.0) 18 (.1) 38 (.1) 45 (.1) 58 (.1)
 Missing time 34 (.3) 85 (.4) 100 (.4) 94 (.3) 105 (.3) 103 (.2)
 No IV rt-PA 12,923 (95.7) 21,058 (95.3) 26,481 (94.7) 33,127 (93.9) 37,714 (93.9) 40,327 (93.2)
IA rt-PA only: Symptom onset to treatment time
 ≤3 hours 2 (.0) 15 (.1) 15 (.1) 21 (.1) 31 (.1) 44 (.1)
 3-4.5 hours 8 (.1) 28 (.1) 32 (.1) 40 (.1) 53 (.1) 97 (.2)
 Beyond 4.5 hours 10 (.1) 71 (.3) 78 (.3) 81 (.2) 119 (.3) 208 (.5)†
 Missing time 18 (.1) 64 (.3) 147 (.5) 224 (.6) 335 (.8) 300 (.7)
 No IA rt-PA 13,461 (99.7) 21,908 (99.2) 27,691 (99.0) 34,923 (99.0) 39,610 (98.7) 42,601 (98.5)
Among those with NIHSS recorded
 Total 4763 8363 12,144 19,680 24,703 30,924
IV rt-PA only: Symptom onset to treatment time
 ≤3 hours 384 (8.1) 666 (8.0) 857 (7.1) 1428 (7.3) 1631 (6.6) 2109 (6.8)†
 3-4.5 hours 27 (.6) 58 (.7) 133 (1.1) 333 (1.7) 430 (1.7) 523 (1.7)†
 Beyond 4.5 hours 2 (.0) 4 (.0) 12 (.1) 33 (.2) 37 (.1) 55 (.2)
 Missing time 21 (.4) 52 (.6) 65 (.5) 82 (.4) 93 (.4) 97 (.3)
 No IV rt-PA 4329 (90.9) 7583 (90.7) 11077 (91.2) 17804 (90.5) 22512 (91.1) 28140 (91.0)
IA rt-PA only: Symptom onset to treatment time
 ≤3 hours 1 (.0) 8 (.1) 14 (.1) 20 (.1) 27 (.1) 41 (.1)
 3-4.5 hours 6 (.1) 17 (.2) 28 (.2) 37 (.2) 50 (.2) 92 (.3)
 Beyond 4.5 hours 7 (.1) 45 (.5) 60 (.5) 71 (.4) 113 (.5) 190 (.6)
 Missing time 11 (.2) 36 (.4) 108 (.9) 181 (.9) 280 (1.1) 265 (.9)
 No IA rt-PA 4738 (99.5) 8257 (98.7) 11,934 (98.3) 19,371 (98.4) 24,233 (98.1) 30,336 (98.1)
Abbreviations: IA, intra-arterial; IV, intravenous; NIHSS, National Institutes of Health Stroke Scale; rt-PA, recombinant tissue plasminogen 
activator.
*
Therapy given at participating hospital.
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†
F-value for trend was significant at a .05 threshold.
‡
IV rt-PA given at an outside hospital and received in transfer by participating hospital.
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Table 3
Outcome comparison among patients who received IV, IA, or combined IV + IA treatments
N (%) by year
Variables Year 2007 Year 2008 Year 2009 Year 2010 Year 2011 Year 2012 P value for trend
Symptomatic ICH
 IV therapy * 60 (5.8) 76 (5.1) 85 (3.9) 107 (4.4) 107 (3.7) .003
 IA therapy * 14 (7.9) 21 (7.7) 27 (7.4) 20 (3.7) 28 (4.3) .003
 IV + IA therapy * 6 (12.8) 3 (4.0) 14(11.3) 14 (8.9) 16 (7.1) NS
Life-threatening complication
 IV therapy * 14 (1.4) 12 (.8) 19 (.9) 18 (.7) 22 (.8) .13
 IA therapy * 3 (1.7) 3(1.1) 2 (.5) 5 (.9) 3 (.5) NS
 IV + IA therapy * 1 (2.1) 3 (4.0) 3 (2.4) 2(1.3) 0 NS
In-hospital mortality
IV therapy 55 (9.5) 88 (8.6) 133 (9.0) 174 (8.0) 169 (6.9) 167 (5.7) <.001
 IA therapy 8 (21.1) 33 (18.5) 48 (17.6) 62 (16.9) 97 (18.0) 95 (14.6) NS
 IV + IA therapy 4 (40.0) 6 (12.8) 21 (28.0) 21 (16.9) 29 (18.4) 24 (10.6) NS
Ambulating at discharge
 IV therapy 177 (30.7) 342 (33.3) 529 (35.7) 747 (34.6) 902 (37.1) 1182(40.4) <.001
 IA therapy 6 (15.8) 38 (21.3) 49 (18.0) 59 (16.1) 110(20.4) 146 (22.5) NS
 IV + IA therapy 3 (30.0) 15 (31.9) 11 (14.7) 20(16.1) 36 (22.8) 63 (27.9) NS
Discharge home
 IV therapy 175 (30.4) 335 (32.6) 534 (36.0) 884 (40.9) 930 (38.2) 1091 (37.3) .0005
 IA therapy 7 (18.4) 38 (21.3) 52(19.1) 71 (19.4) 103 (19.1) 127 (19.6) NS
 IV + IA therapy 3 (30.0) 12 (25.5) 11 (14.7) 19 (15.3) 37 (23.4) 52 (23.0) NS
Abbreviations: IA, intra-arterial; ICH, intracerebral hemorrhage; IV, intravenous; NS, not significant.
*
Data not available.













Asaithambi et al. Page 11
Table 4
Comparison of in-hospital outcomes between patients who received IV treatment and those who received IA 
or combined IV + IA treatments by NIHSS scores
N (%) by NIHSS
Variables NIHSS < 10 P value NIHSS ≥ 10 P value
In-hospital mortality
 IV therapy only 72 (1.7) <.0001 549(11.1) <.0001
 IA therapy only 27 (6.7) 240 (18.4)
 IV + IA therapy 6 (7.6) 86 (16.7)
 Ambulated at discharge
 IV therapy only 2310(55.1) <.0001 1116(22.6) <.0001
 IA therapy only 163 (40.3) 175 (13.4)
 IV + IA therapy 32 (40.5) 111 (21.6)
Discharge home
 IV therapy only 2329 (55.5) <.0001 1136 (23.0) <.0001
 IA therapy only 160 (39.6) 161 (12.3)
 IV + IA therapy 35 (44.3) 95 (18.4)
Abbreviations: IA, intra-arterial; IV, intravenous; NIHSS, National Institutes of Health Stroke Scale.
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